| answer text |
<p>It is still too early to establish the impact of COVID-19 on the spread of antimicrobial
resistance. The UK is supporting countries to respond to the pandemic, maintain essential
health services, including diagnosis and treatment of infectious diseases like TB,
and to strengthen health systems to combat antimicrobial resistance. This includes
our investments in WHO, Global Fund and Gavi as well as bilateral support to country
health systems.</p><p>The FCDO funds research programmes to promote the development
of new diagnostics, medicines and vaccines. For TB and multidrug-resistant-TB, this
includes our support to the Foundation for Innovative New Diagnostics (FIND). With
our support, FIND have developed five new diagnostic tests for TB, now approved by
WHO and being rolled out in over 27 countries. FCDO also funds UNITAID, which aims
to triple access to rapid testing for MDR-TB, and to reduce MDR-TB drug prices.</p>
|
 |
